Avoid hypersensitivity reactions to the anti-HIV drug Abacavir by HLA-B*57:01 genotyping.

HLA-B*57:01 is a genetic risk factor for hypersensitivity reactions to abacavir, an antiretroviral drug used in HIV therapy. The HLA-B5701 RealFast™ Assay determines the presence or absence of HLA-B*57:01 alleles in patients.

 

HLA-B5701

 

  • Abacavir is used in antiretroviral combination therapy for the treatment of HIV-infected patients.
  • The HLA-B*57:01 allele, a variant of the human leukocyte antigen B (HLA-B) gene, is strongly associated with abacavir hypersensitivity. HLA-B*57:01 positive patients must be excluded from such treatment.
  • Screening of patients for the presence of HLA-B*57:01 before starting abacavir therapy reduces the incidence of hypersensitivity reactions (HSR).

 

ProductREFUnit SizeIFUBrochure
HLA-B5701 RealFast™ Assay7-610
7-613
100 rxn
32 rxn

PDF

PDF